Key Findings
Efficient molecular therapeutic delivery to the central nervous system (CNS) continues to be a significant challenge for neurogenetic disorders such as Niemann-Pick Disease Type C (NPC). This preprint study evaluated Focused ultrasound-mediated blood-brain barrier opening (FUS-BBBO) as a non-invasive strategy to deliver lipid nanoparticle (LNP)-packaged modified mRNA (modRNA) to the cerebellum in an NPC mouse model. Although FUS-BBBO reliably induced BBB opening and facilitated limited LNP-mRNA delivery to the brain, it did not, under the tested conditions, result in detectable protein expression or therapeutic effects.
Technical/Clinical Details
Niemann-Pick Disease Type C (NPC) is a rare neurodegenerative disorder caused by abnormal intracellular cholesterol transport, leading to severe neurological symptoms with no effective treatments currently available. mRNA therapy is a promising modality for protein replacement or gene editing but its delivery to the brain is hindered by the BBB. FUS-BBBO is a non-invasive technique that uses low-intensity focused ultrasound in conjunction with microbubbles to transiently and reversibly open the BBB. In this study, FUS-BBBO was employed in an NPC mouse model to deliver LNP-packaged modRNA to the cerebellum. Histological analysis confirmed that FUS-BBBO reliably induced BBB opening and, to some extent, promoted the entry of LNP-mRNA into brain tissue. However, no protein expression from the delivered modRNA was detected, and consequently, no measurable therapeutic effects on disease biomarkers or pathophysiology were observed. This suggests that there are still challenges regarding the efficiency of FUS-BBBO-mediated LNP-mRNA brain delivery, as well as intracellular uptake and translational efficiency.
Background & Context
The challenge of BBB permeability in treating brain diseases has been a long-standing bottleneck in drug discovery. LNP-packaged mRNA, in particular, has garnered significant attention following the success of COVID-19 vaccines, but tissue-specific delivery, especially to the brain, still faces substantial barriers. FUS-BBBO is widely investigated as a promising non-invasive technique to open the BBB for gene therapy and drug delivery in neurological disorders. Previous studies have reported successful brain delivery of small molecule drugs and some antibodies. However, this study clarifies that further optimization is required for the delivery and intracellular functional expression of larger complexes like LNP-mRNA.
Strategic Significance & Outlook
These findings indicate that further optimization is necessary for FUS-BBBO-mediated LNP-modRNA brain delivery to be an effective therapeutic strategy for neurogenetic diseases like NPC. Future research will likely explore adjustments to FUS-BBBO parameters (e.g., ultrasound intensity, microbubble size and concentration), improvements in LNP composition or surface modifications, or design changes to enhance mRNA stability and translational efficiency. Despite the current limitations, the potential for FUS-BBBO combined with LNP-modRNA to revolutionize neurological disease treatment remains high, and further research is anticipated. For example, developing technologies that enable more localized delivery and targeting of specific cell types will be crucial.
Source: https://www.biorxiv.org/content/10.64898/2026.06.30.735564v1
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments